AQST
Aquestive Therapeutics, Inc.Company with tickers: AQST
CIK
1398733
CUSIP
03843E104
Shares Outstanding
125,450,119
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $14,446,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $4,204,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Operating Income | $-4,204,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| Net Income | $-8,057,000 | USD | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Basic) | $-0.07 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |
| EPS (Diluted) | $-0.07 | USD/shares | 2026-03-31 | 10-Q | 2026-05-13 |